ArticleMolecular cancer therapeutics2026
ABL209 (NEOK002): Designing an EGFR × MUC1 Bispecific TOP1i ADC with Promising Antitumor Activity and Enhanced Therapeutic Window.
Bora Lee et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.